– USA, CA – Pacific Biosciences of California, Inc. (Nasdaq: PACB), a leading provider of high-quality sequencing of genomes, transcriptomes and epigenomes, today announced that industry veteran Christian Henry has been appointed to serve as Chairman of its Board of Directors.
The Board of Directors decided to separate the Chairman and Chief Executive Officer positions in alignment with best practices.
Mr. Henry will become Chairman of the Board, effective immediately and Dr. Michael Hunkapiller will continue to serve as President and CEO, as well as an active member of the board.
Previously, Dr. Michael Hunkapiller held the combined roles of Chairman, President and CEO of Pacific Biosciences, and William Ericson, a founding partner at Wildcat Venture Partners, held the role of Lead Independent Director of Pacific Biosciences. With the appointment of Christian Henry as the independent Chairman of the Board, Mr. Ericson will step down as Lead Independent Director, and will also continue to serve as a member of the company’s board.
Henry, who has over 20 years of leadership experience and was previously Executive Vice President and Chief Commercial Officer at Illumina, joined the board in July 2018 and has served on its Compensation Committee since June 2019.
“Christian’s deep domain expertise has been a valuable addition to our Board,” said Dr. Hunkapiller. “Having an independent board chair is considered a corporate governance best practice, and Christian’s experience at Illumina will serve him well in that role.”
“I am pleased and honored to take on the role of Chairman,” said Mr. Henry. “I joined the Board because of my enthusiasm for PacBio’s truly unique SMRT Sequencing technology and commercial potential. I look forward to continuing to work with the company’s board and management team to drive even greater adoption of PacBio’s products in the global sequencing market.”
About Pacific Biosciences
Pacific Biosciences of California, Inc.offers sequencing systems to help scientists resolve genetically complex problems. Based on its novel Single Molecule, Real-Time technology, Pacific Biosciences’ products enable: de novo genome assembly to finish genomes in order to more fully identify, annotate and decipher genomic structures; full-length transcript analysis to improve annotations in reference genomes, characterize alternatively spliced isoforms in important gene families, and find novel genes; targeted sequencing to more comprehensively characterize genetic variations; and real-time kinetic information for epigenome characterization. Pacific Biosciences’ technology provides high accuracy, ultra-long reads, uniform coverage, and the ability to simultaneously detect epigenetic changes. PacBio sequencing systems, including consumables and software, provide a simple, fast, end-to-end workflow for SMRT Sequencing.
For more information: https://www.pacb.com
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.
